We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cancer therapies

News List

Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation AmericanPharmaceuticalReview
December 02, 2021
Ranok Therapeutics (Hangzhou) Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, today announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platfor...
CRISPR and MaxCyte sign licensing deal for cancer therapies pharmaceutical-technology
November 13, 2018
Swiss gene editing firm CRISPR Therapeutics has signed a non-exclusive commercial licence agreement with US-based drug maker MaxCyte for the development of new immuno-oncology therapies.
Race and TargImmune to develop new cancer therapies pharmaceutical-technology
July 12, 2017
Australian-based specialist pharmaceutical firm Race Oncology has executed a Letter of Intent (LoI) with Swiss-based biotechnology TargImmune Therapeutics to enter a joint venture (JV) between the two companies to develop new and improved cancer therapies